Adaptimmune Therapeutics shares rise 5.21% intraday as T-cell therapy market forecast shows growth to $17.8B by 2034.

Adaptimmune Therapeutics Plc surged 5.21% intraday as a clinical trial market report projected the global T-cell immunotherapy market to grow from $5.2 billion in 2024 to $17.8 billion by 2034, with a compound annual growth rate of 13.2%. The company specializes in developing engineered T-cell therapies for cancer treatment.